Tissue Regenix Group PLC CEO and CFO Share Purchases (3905V)
April 05 2023 - 1:00AM
UK Regulatory
TIDMTRX
RNS Number : 3905V
Tissue Regenix Group PLC
05 April 2023
Tissue Regenix Group plc
('Tissue Regenix' or the 'Company')
CEO and CFO Share Purchases
Tissue Regenix (AIM: TRX), the regenerative medical device
company, announces that on 4 April 2023, Daniel Lee, Chief
Executive Officer, and David Cocke, Chief Financial Officer each
purchased 1,428,570 of the Company's ordinary shares of 0.1p each
("Ordinary Shares").
Name Title Number of Resulting Percentage
Ordinary beneficial of Company's
Shares purchased interest in Total Voting
the Company's Rights
Ordinary Shares
Daniel Lee Chief Executive Officer 1,428,570 8,690,770 0.12%
David Cocke Chief Financial Officer 1,428,570 7,120,570 0.10%
------------------------- ------------------ ----------------- --------------
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
finnCap Ltd (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR & IR) Tel: +44(0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field
of regenerative medicine. The Company's patented decellularisation
technology ('dCELL(R)') removes DNA and other cellular material
from animal and human soft tissue, leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or damaged body structures. Current
applications address many critical clinical needs in sports
medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specialises in regenerative
medicine and is dedicated to the development of high quality,
innovative tissue scaffolds, which can enhance healing
opportunities in defects created by trauma and disease.
CellRight(R)'s human tissue products may be used in spine, trauma,
general orthopaedic, dental and ophthalmological surgical
procedures.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Daniel Lee
--------------------------------------- ---------------------------------------
Reason for the notification
2
--------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
--------------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ---------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------------------------- ---------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------------------------- ---------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1p each
financial instrument,
type of instrument
Identification code GB00B5SGVL29
b) Nature of the transaction Purchase
--------------------------------------- ---------------------------------------
c) Price(s) and volume(s)
----------------- -----------------
Price(s) Volume(s)
----------------- -----------------
0.5700p 500,000
----------------- -----------------
0.5650p 928,570
----------------- -----------------
d) Aggregated information
- Aggregated volume 1,428,570
- Price GBP8,096.42
e) Date of the transaction 4 April 2023
--------------------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------------------- ---------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name David Cocke
--------------------------------------- ---------------------------------------
Reason for the notification
2
--------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ---------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------------------------- ---------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------------------------- ---------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1p each
financial instrument,
type of instrument
Identification code GB00B5SGVL29
b) Nature of the transaction Purchase
--------------------------------------- ---------------------------------------
c) Price(s) and volume(s)
----------------- -----------------
Price(s) Volume(s)
----------------- -----------------
0.5700p 500,000
----------------- -----------------
0.5650p 928,570
----------------- -----------------
d) Aggregated information
- Aggregated volume 1,428,570
- Price GBP8,096.42
e) Date of the transaction 4 April 2023
--------------------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------------------- ---------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHKZGGDRDKGFZM
(END) Dow Jones Newswires
April 05, 2023 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024
